Clinical Research Directory
Browse clinical research sites, groups, and studies.
Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection
Sponsor: Taichung Veterans General Hospital
Summary
tenofovir alafenamide (TAF) has been approved to be highly effective and safe in patients with chronic hepatitis B (CHB), therefore TAF may be a good option in kidney or liver transplant patients with chronic HBV infection. The aim of this prospective cohort study is to assess the safety, efficacy, and drug adherence improvement of TAF switching therapy in kidney or liver transplant patients with HBV infection.
Official title: A Prospective Cohort Study of Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic Hepatitis B Virus Infection
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
52
Start Date
2021-06-22
Completion Date
2027-07-30
Last Updated
2025-01-09
Healthy Volunteers
No
Interventions
Tenofovir Alafenamide 25 MG
To assess the safety, efficacy, and drug adherence improvement of TAF switching therapy in kidney or liver transplant patients with HBV infection.
Locations (2)
Taichung Veterans General Hospital
Taichung, Taiwan, Taiwan
China Medical University Hospital
Taichung, Taiwan